Workflow
港股异动|MIRXES-B(02629)涨近9%创新高 公司在基于miRNA的癌症早期检测领域优势显著
MIRXESMIRXES(HK:02629) Jin Rong Jie·2025-08-15 04:06

Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, reaching a new high of 40.66 HKD, which is over 70% higher than its IPO price of 23.3 HKD [1] Company Overview - Mirxes is a Singapore-based RNA biotechnology company focused on developing and commercializing precise, non-invasive, and affordable blood miRNA tests for early cancer and disease screening [1] - The flagship product, GASTROClear™/觅小卫™, is a blood miRNA-based molecular diagnostic kit for gastric cancer screening, approved in multiple countries including Singapore and the EU, and has received breakthrough medical device certification from the US FDA [1] - GASTROClear™ has completed a prospective clinical trial with a sample size of 9,472 in China and is currently in the registration application process [1] Market Position - The company is recognized as a global leader in the field of early cancer detection based on miRNA, possessing significant technological, product, and market advantages [1] - The global cancer screening market is noted to have vast potential with high entry barriers [1] - GASTROClear™ is the only approved molecular diagnostic IVD product for gastric cancer screening in the global market, holding the largest market share of 66.3% in the Southeast Asian miRNA-based liquid biopsy gastric cancer screening market as of 2023 [1]